Sodium-glucose cotransporter 2 inhibitor in heart failure patients and their outcomes: A meta-analysis of randomized controlled trials
These results suggest that SGLT2 inhibitor significantly reduce the risk of hospitalization for HF, CV deaths, and all-cause mortality.
Authors
- Salim Surani
- Lakshmi Priyanka Mahali
- Rahul Kashyap (ORCID: https://orcid.org/0000-0002-5700-282X)
- Pallavi Shirsat (ORCID: https://orcid.org/0000-0003-4969-3488)
- Saketh Parsi (ORCID: https://orcid.org/0009-0000-6721-6875)
Institutions
- WellSpan Health (US)
- Yale New Haven Health System (US)
- Johannes Wesling Klinikum Minden (DE)
- Seton Medical Center Austin (US)
- Texas A&M University (US)
Publication Details
- Journal
- World Journal of Cardiology
- Published
- 2025-10-23
- DOI
- https://doi.org/10.4330/wjc.v17.i10.109731
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29